For more on MASLD and MASH, be sure to check out our 10/30 webinar, Noninvasive biomarker testing for liver fibrosis: The laboratory’s role in advancing MASLD and MASH patient management.
Description
This webinar will explore the rising prevalence of MASLD and MASH in the US and their growing impact on the healthcare system. Attendees will gain insight into the risk factors and comorbidities that influence disease progression and management. The webinar will also highlight the role of noninvasive tests (NITs) in diagnosis and care, with a focus on current US clinical guidelines. Our speaker, Dr Zobair Younossi, will provide practical guidance for supporting test selection to improve early identification and outcomes for patients with liver disease.
Target audience
This activity is designed for physicians, lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), fellows, residents, and other laboratory professionals overseeing/conducting within this topic.
Learning objectives
At the end of this webinar, participants will be able to:
- Discuss the growing prevalence and incidence of MASLD and MASH in the US and their impact on the healthcare system.
- Summarize the risk factors and comorbid conditions associated with MASLD and MASH and the impact of these conditions on the progression and management of liver disease.
- Recognize the role of noninvasive testing in diagnosis and management of MASLD and MASH based on key recommendations from several US guidelines.
Faculty
Zobair M. Younossi, MD, MPH
Professor and Chairman
Global NASH/MASH Council Center for Outcomes Research in Liver Disease
Washington, DC
Disclosures and statement of independence
The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.
The following faculty reported financial relationships:
- Zobair M. Younossi, MD, MPH
- Honorarium/Expenses: BMS, GSK, Akero, Cymabay, Ipsen, Aventiva, Gilead, AbbVie, Abbott, Novo Nordisk, Madrigal, Merck, Siemens, and Intercept
- Grant Support: Novo Nordisk and Madrigal
Content validity
All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.
Accreditation statement
This activity is approved for 1.0 ACCENT® continuing education credits. Activity ID #4448. This activity was planned in accordance with ACCENT® Standards and Policies.
Successful completion statement
Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email education@myadlm.org.
